Anti-thrombotics in thrombosis and cancer

Future Oncology

Volumn 1, Issue 3, 2005, Pages 395-403

  Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

angiogenesis; aspirin; cancer; coagulation; fibroblast growth factor 2; glycoprotein IIb IIIa antagonists; heparin; lowmolecular weight heparin; platelet; tissue factor pathway inhibitor; tissue factor VIIa; tumor dissemination; vascular endothelial growth factor; venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

BLOOD; BLOOD CLOTTING; DRUG EFFECT; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET ACTIVATION; THROMBOSIS;

EID: 33646450607     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.3.395     Document Type: Review

References (66)

1. Mousa SA: Anticoagulants in thrombosis and cancer: the missing link. Semin. Thromb. Haemostasis 28, 45-52 (2002).
2. Mousa SA: Comparative efficacy among different low molecular weight heparin (LMWHs) and drug interaction: implications in the management of vascular disorders. Semin. Thrombosis Hemostasis. 26 (1 Suppl.) 1, 39-46 (2000).
3. Chambers AF: The metastatic process: basic research and clinical implications. Oncol. Res. 11, 161-168 (1999).
4. Chambers AF, MacDonald IC, Schmidt EE et al.: Steps in tumor metastasis: new concepts from intra-vital video microscopy. Cancer Metastasis Rev. 14, 279-301 (1995).
5. Borsig L, Wong R, Feramisco J et al.: Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA 98, 3352-3357 (2001).
6. Koenig A, Norgard-Sumnicht K, Linhardt R et al.: Differential interactions of heparin and heparin sulfate glycosaminoglycans with the selectins. J. Clin. Invest. 101, 877-889 (1998).
7. Varki A, Varki NM: P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz. J. Med. Biol. Res. 34, 711-727 (2001).
8. Trousseau A: Phlegmasia alba dolens. In:Clinique de lHotel-Dieu de Paris , 2nd Edn Baillier JB (Ed.) London, New Sydenham Society 3, 94 (1865).
9. Schiller H, Bartscht T, Arlt A et al.: Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro. Int. J. Clin. Pharmacol. Ther. 40, 329-335 (2002).
10. Sorensen H, Mellemkjaer L, Olsen J et al.: Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846-1850 (2000). 11. Caine GJ, Lip GY: Anticoagulants as anticancer agents? Lancet Oncol. 3, 591-592 (2002).
11. Lebeau B, Chastang C, Brechot J-M et al.: Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74, 38-45 (1994).
12. Chahinian A, Propert K, Ware J et al.: A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukaemia Group B. J. Clin. Oncol. 7, 993-1002 (1989).
13. Thornes R: Coumarins, melanoma and cellular immunity. In:Protective Agents in Cancer . McBrien D, Slator T (Eds), Academic Press, UK, 43-56 (1983).
14. Saba HI, Khalil FK, Morelli GA et al.: Thromboembolism preceding cancer: a correlation study. Am. J. Hematol. 72, 109-114 (2003).
15. Goldberg RJ, Seneff M, Gore JM: Occult malignant neoplasm in patients with deep venous thrombosis. Ann. Intern. Med. 147, 251-253 (1987).
16. Baron JA, Gridley G, Weiderpass E et al.: Venous thromboembolism and cancer. Lancet 351, 1077-1080 (1998).
17. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseaus syndrome revisited. Blood 62, 14-31 (1982).
18. Levine MN: Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb. Haemost. 78, 133-136 (1997).
19. Falanga A: Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 28, 50-60 (1998).
20. Kakkar AJ, De Ruvo N, Tebbutt S et al.: Extrinsic pathway activation with elevated tissue factor and Factor VIIa in patients with cancer. Lancet 346, 1004-1005 (1995).
21. Simonneau G, Sors H, Charbonnier B et al.: A comparison of low-molecularweight heparin with unfractionated heparin for acute pulmonary embolism. N. Engl. J. Med. 337, 663-669 (1997).
22. Koopman MMW, Prandoni P, Piovella F et al.: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334, 682-687 (1996).
23. Pintucci G, Froum S, Pinnell J et al.: Tropic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb. Haemost. 88, 834-842 (2002).
24. Manegold PC, Hutter J, Pahernik SA et al.: Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood 101, 1970-1976 (2003).
25. Werther K, Christensen IJ, Nielsen HJ: Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand. J. Clin. Lab. Invest. 62, 343-350 (2002).
26. Verheul HM, Pinedo HM: Tumor growth: a putative role for platelets? Oncologist 3, II (1998).
27. Verheul HM, Hoekman K, Luykx-de Bakker S et al.: Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 3, 2187-2190 (1997).
28. Amirkhosravi A, Amaya M, Desai H et al.: Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular pro-coagulant activity. Blood Coagul. Fibrinolysis 13, 505-512 (2002).
29. Gasic GJ, Gasic TB, Stewart CC: Antimetastatic effect associated with platelet reduction. Pathology 61, 46-52 (1998).
30. Karpatkin S, Pearlstein E, Ambrogio C et al.: Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J. Clin. Invest. 81, 1012-1019 (1988).
31. Trikha M, Zhou Z, Timar J et al.: Multiple roles for platelet GPIIb/IIIa and áv3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 62, 2824-2833 (2002).
32. Varki NM, Varki A: Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. 28, 53-66 (2002).
33. Kakkar AJ, Williamson RC. Prevention of venous thromboembolism in cancer using low molecular weight heparin. Haemostasis 27, 32-37 (1997).
34. Zacharski LR, Ornstein DL: Heparin and cancer. Thromb. Haemost. 80, 10-23 (1998).
35. von Tempelhoff GF, Harenberg J, Neimann F et al.: Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int. Oncol. 16, 815-824 (2000).
36. Zacharski LR: Anticoagulant in cancer treatment: malignancy as a solid-phase coagulopathy. Cancer Lett. 186, 1-9 (2002).
37. Meyers G, Marjanovic Z, Valcke J et al.: Comparison of LMWH and wafarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch. Intern. Med. 162, 1729-1735 (2002).
38. Trousseau A. Plegmasia alba dolens. In:Clinique de lHotel-Dieu de Paris , 2nd Edn. In Baillier JB (Ed.) London: New Syndenham Society 3, 654-712 (1865).
39. Haward W: Phlebitis and thrombosis. Lancet 1, 650-655 (1906).
40. Dvorak HF: Thrombosis and cancer. Hum. Pathol. 18, 275-284 (1987).
41. Kakkar AK, Levine MN, Prandoni P et al.: What is the role for antithrombotics in cancer care? Interactive session with panel discussion. Cancer Treat. Rev. 28, 157-159 (2002).
42. Dvorak HF, Senger DR, Dvorak AM: Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 2, 41-73 (1983).
43. Hirsh J, Levine MN: Low molecular weight heparin. Blood 79, 1-17 (1992).
44. Nielsen JI, Ostergaard P: Chemistry of heparin and low molecular weight heparin. Acta. Chir. Scand. Suppl. 543, 52-56 (1988).
45. Engelberg H: Actions of heparin that may affect the malignant process. Cancer 85, 257-272 (1999).
46. Linhardt RJ, Gunay NS: Production and chemical processing of low molecular weight heparins. Semin. Thromb. Haemostasis 25, 5-16 (1999).
47. Mousa SA, Kaiser B: Tissue factor pathway inhibitor in thrombosis and beyond. Drugs of the Future 29(7), 755-766 (2004).
48. Hull RD, Raskob GE, Pineo GF et al.: Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326, 975-982 (1992).
49. Levine M, Hirsh J, Gent M et al.: Doubleblind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343, 886-889 (1994).
50. Mousa SA, Mousa AS: Angiogenesis inhibitors: current and future directions. Curr. Pharma. Design 10(1), 1-9 (2004).
51. Mousa SA, Mohamed S: Antiangiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anticancer efficacy. Oncol. Rep. 12, 683-688 (2004).
52. Folkman J, Shing Y: Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol. 313, 355-364 (1992).
53. Mousa SA, Mohamed S: Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thrombosis Haemostasis 92, 627-633 (2004).
54. Amirkhosravi A, Mousa SA, Amaya M et al.: Antimetastatic effect of tinzaparin, a low molecular weight heparin. J. Thromb. Haemostasis 1, 1972-1976 (2003).
55. Ludwig, RJ, Boehme B, Podda M et al.: Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 64, 2743-2750 (2004).
56. Falanga A, Rickles FR: Pathophysiology of the thrombophilic state in the cancer patient. Semin. Thromb. Hemost. 25, 173-182 (1999).
57. Markus G: The role of haemostasis and fibrinolysis in the metastatic spread of cancer. Thromb. Haemost. 10, 61-72 (1984).
58. Ruf W, Mueller BM: Tissue factor in cancer angiogenesis and metastasis. Curr. Opin. Hematol. 3, 379-384 (1996).
59. Paredes N, Xu L, Berry LR et al.: The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br. J. Haematol. 120, 315-324 (2003).
60. Pinedo H, Verheul H, DAmato R et al.: Involvement of platelets in tumor angiogenesis? Lancet 352, 1775-1777 (1998).
61. Wojtukiewicz M, Zacharski L, Memoli V et al.: Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res. 10, 579-582 (1990).
62. Zacharski L, Wojtukiewicz M, Costantini V et al.: Pathways of coagulation/fibrinolysis activation in malignancy. Semin. Thromb. Hemostasis 18, 104-116 (1992).
63. Zhang Y, Deng Y, Luther T et al.: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 94, 1320-1327 (1994).
64. Engelberg H: Actions of heparin in the atherosclerotic process. Pharmacol. Rev. 48, 327-352 (1996).
65. Mousa SA: Anticoagulants in thrombosis and cancer: the missing link. Expert Rev. Anticancer Ther. 2, 227-233 (2002).
66. Rickles FR, Levine MN: Epidemiology of thrombosis in cancer. Acta Haematol. 106, 6-12 (2001).